Hikma Pharmaceuticals has signed an agreement to acquire for $17.0m pipeline epinephrine and naloxone nasal sprays and a complementary manufacturing platform from Insys Therapeutics, which recently filed for bankruptcy. Both the epinephrine and naloxone sprays are intended for approval through the US Food and Drug Administration’s hybrid 505(b)(2) regulatory pathway.
Speaking exclusively to Generics Bulletin immediately after announcing the deal, Hikma’s CEO Siggi Olafsson described the Insys assets acquisition as “a small example that reflects the strategy that I have been talking about on mergers and acquisitions, where transformation is not our focus
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?